Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus

American Journal of Reproductive Immunology

Volumn 49, Issue 5, 2003, Pages 279-284

  Keller, M J ^a   Klotman, M E ^a   Herold, Betsy C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Genital tract; Inflammation; Microbicide; Sexually transmitted infections

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CARRAGEENAN; CELLULOSE SULFATE; CYANOVIRIN; CYTOKINE; DEXTRAN SULFATE; GAG PROTEIN; GLYCOPROTEIN GP 120; INTERLEUKIN 1; MANDELIC ACID; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; POLYSACCHARIDE SULFATE; POLYSTYRENESULFONIC ACID; PRO 2000; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ASSAY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENITAL SYSTEM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY CELL; MUCOSA CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINA DISEASE;

ANTI-INFECTIVE AGENTS, LOCAL; HERPES SIMPLEX; HIV; HIV INFECTIONS; HUMANS; SIMPLEXVIRUS;

EID: 0037716610     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0897.2003.00044.x     Document Type: Review

References (50)

1. UNAIDS: Report on the Global HIV/AIDS Epidemic: December 2001 Update.
2. Mauck C, Rosenberg Z, Van Damme L: Recommendations for the clinical development of topical microbicides: An update. AIDS 2001; 15: 857-868.
3. Hardy E, De Padua KS, Jimenez AL, Zaneveld LJ: Women's preferences for vaginal antimicrobial contraceptives. II. Preferred characteristics according to women's age and socioeconomic status. Contraception 1998; 58: 239-244.
4. Van Damme L, Wright A, Depraetere K et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect 2000; 76:126-130.
5. Rustomjee R, Abdool Karim Q, Abdool Karim SS, Laga M, Stein Z: Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS 1999; 13: 1511-1515.
6. Howett MK, Neely EB, Christensen ND et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother 1999; 43: 314-321.
7. Rusconi S, Moonis M, Merrill DP et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40:234-236.
8. Pearce-Pratt R, Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996; 54:173-182.
9. Herold BC, Scordi-Bello I, Cheshenko N et al. Mandelic acid condensation polymer: Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J Virol 2002; 76: 11236-11244.
10. Dragic T, Trkola A, Thompson DA et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 2000; 97:5639-5644.
11. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA: Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000; 74:4562-4569.
12. Tsai CC, Follis KE, Sabo A, Grant R, Bischofberger N: Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 1995; 171:1338-1343.
13. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA: Chemical barriers to human immunodeficiency virus type-1 (HIV-1) infection. Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997; 71:3023-3030.
14. Patterson BK, Landay A, Andersson J et al. Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol 1998; 153:481-490.
15. Zhang L, He T, Talal A, Wang G, Frankel SS, Ho DD: In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 1998; 72:5035-5045.
16. Herold BC, Kirkpatrick R, Marcellino D et al. Bile salts: Natural detergents for the prevention of sexually transmitted diseases. Antimicrob Agents Chemother 1999; 43:745-751.
17. From the Centers of Disease Control and Prevention: CDC treatment of study results of product containing nonoxynol-9. JAMA 2000; 284:1376.
18. Baba M, Schols D, De Clercq E et al. Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation. Antimicrob Agents Chemother 1990; 34:134-138.
19. Flexner C, Barditch-Crovo PA, Kornhauser DM et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35:2544-2550.
20. Meylan PR, Kornbluth RS, Zbinden I, Richman DD: Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. Antimicrob Agents Chemother 1994; 38:2910-2916.
21. Long EM, Martin HL, Kreiss JK et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71-75.
22. Harouse JM, Tan RC, Gettie A et al. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 1998; 248:95-107.
23. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud JP, Montagnier L: Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr 1993; 6:72-75.
24. Vogt MW, Witt DJ, Craven DE et al. Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet 1986; 1:525-527.
25. Wofsy CB, Cohen JB, Hauer LB et al. Isolation of AIDS-associated retroviruses from genital secretions of women with antibodies to the virus. Lancet 1986; 1:527-529.
26. Levy JA: The transmission of AIDS: The case of the infected cell. JAMA 1988; 259:3037-3038.
27. Levy JA: The transmission of HIV and factors influencing progression to AIDS. Am J Med 1993; 95:86-100.
28. Miller CJ, Vogel P, Alexander NJ, Sutjipto S, Hendrickx AG, Marx PA: Localization of SIV in the genital tract of chronically infected female rhesus macaques. Am J Pathol 1992; 141:655-660.
29. Hu J, Gardner MB, Miller CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087-6095.
30. Spira AI, Marx PA, Patterson BK et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macques. J Exp Med 1996; 183:215-225.
31. Cohen MS: Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis. Lancet 1998; 351:5-7.
32. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L: Frequency recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-66.
33. Poli G, Fauci AS: A role of cytokine in the pathogenesis of human immunodeficiency virus infection. In Human Cytokines: Their Role in Disease and Therapy. B Aggarwahl, R Puri (eds). Cambridge, MA, Blackwell Science 1995, pp. 421-449.
34. Moriuchi M, Moriuchi H, Williams R, Straus SE: Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology 2000; 278:534-540.
35. Moulard M, Lortat-Jacob H, Mondor I et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74:1948-1960.
36. Herold BC, Bourne N, Marcellino D et al. Poly(sodium 4-styrene sulfonate): An effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J Infect Dis 2000; 181:770-773.
37. Alliance for Microbicide Development: Available at: http://www.microbicide.com.
38. Goulston C, McFarland W, Katzenstein D: Human immunodeficiency virus type 1 RNA shedding in the female genital tract. J Infect Dis 1998; 177:1100-1103.
39. Rasheed S, Li Z, Xu D, Kovacs A: Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 1997; 175:122-129.
40. Baron P, Bremer J, Wasserman SS et al. Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. J Clin Microbiol 2000; 38:3822-3824.
41. Cu-Uvin S, Caliendo AM, Reinert S et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421.
42. Hart CE, Lennox JL, Pratt-Palmore M et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-882.
43. Iversen AK, Larsen AR, Jensen T et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998; 177:1214-1220.
44. Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ: Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 1999; 2:154-166.
45. Mayer KH, Kelly C, Morar NS, Maslankowski L, Emans A, Welsh J: The safety and tolerability of PRO 2000 gel, a novel vaginal microbicide, in sexually active HIV- and abstinent HIV+ women. Berlin, Germany, International Congress of Sexually Transmitted Infections 2001
46. Garcia-Blanco MA, Cullen BR: Molecular basis of latency in pathogenic human viruses. Science 1991; 254:815-820.
47. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:1141-1149.
48. Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:417-428.
49. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA: Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000; 62:149-154.
50. Moore JP, Stevenson M: New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000; 1:40-49.